Skip to main content
. 2015 Mar;5(3):a021493. doi: 10.1101/cshperspect.a021493

Table 2.

Comparisons of the prevention of HBV infection in infants or immunogenicity of different strategies among different risk groupsa

Infants of HBsAg+, HBeAg+ mothers Infants of HBsAg+, HBeAg mothers Immunogenicity in low-risk infants (infants or children of HBsAg mothers)
HBIG only (Beasley et al. 1983b)
 One dose, 1.0 mL HBsAg+, 54%, efficacy 45%
 Three doses, 0.5 mL HBsAg+, 26%, efficacy 75%
 Placebo HBsAg+, 92%
HBV plasma vaccine Vaccine, three doses (RP Beasley and L-Y Hwang, unpubl.)
1 wk, 1, 6 mo, HBsAg+, 23%
1, 2, 6 mo, HBsAg+, 38%
Placebo HBsAg+, 88%
Vaccine, four doses (Tsai et al. 1984), HBsAg+, 0%
Placebo, HBsAg+, 5.3%
Anti-HBs (Lee et al. 1983)
After one dose, 48%
After two doses, 96%
After three doses, 100%
Combination of HBV plasma vaccine and HBIG, 0.5 mL/dose HBIG birth, 3 mo + vaccine, 3, 4, 9 mo, HBsAg 2.0% (Beasley et al. 1983c) HBIG + vaccine, 0, 1, 6 mo, HBsAg+, <1% (Yang et al. 2003)
HBIG birth + vaccine 0, 1, 6 mo, HBsAg+, 6.0% (Beasley et al. 1983c) Vaccine, 0, 1, 6 mo, HBsAg+ <1%
HBIG birth + vaccine, 1, 2, 7 mo, HBsAg+, 8.6% (Beasley et al. 1983c)
HBIG birth + vaccine, 0, 1, 2, 12 mo, HBsAg+, 11% (Hsu et al. 1988)
Placebo, HBsAg+, 88.1% (Beasley et al. 1983c)
Combination of HBV recombinant vaccine + one dose HBIG, 0.5 mL HBIG + vaccine 0, 1, 6 mo, HBsAg+, 3.3% (Lee et al. 1991)
HBIG + vaccine, 0, 1, 6 mo, HBsAg+, 9.26% (Chen et al. 2012)
HBIG + vaccine 0, 1, 6 mo, HBsAg+, 0.14% (Chen et al. 2012)
Vaccine, 0, 1, 6 mo, HBsAg+, 0.29%

aHBsAg+ rate in high-risk infants (in comparison to controls with no vaccine or HBIG).